A Trial Comparing Qam With Qpm Dosing in Assisted Reproductive Technologies (ART)

This is a prospective randomized trial comparing the outcome in women undergoing IVF/ICSI when taking their gonadotropin dosage in the morning (am) or evening (pm).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Genital Diseases Urogenital Diseases

Age range

21 year–42 year

Sex eligibility

Female

Study type

Observational

Primary location

Virginia Center for Reproductive Medicine

Reston, Virginia, 20190, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

women between 21-42 undergoing IVF

Exclusion criteria

women > 45,
women with one ovary,
donor egg,
surrogacy,
FET cycles,
uterine problems,
large fibroids

Treatment and study plan

Primary outcomes

Live birth rate

Time frame: 4 years

Sponsors and collaborators

Lead sponsor

Virginia Center for Reproductive Medicine

Other

Registry information

Official study title

A Prospective Randomized Trial Comparing Qam With Qpm Daily Dosing in Assisted Reproductive Technologies

Important dates

Study start: 2010
Primary completion: 2015
Study completion: 2015
First posted: Jun 8, 2010
Registry last updated: Dec 9, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed